Edwards Lifesciences (EW) Depreciation & Amortization (CF) (2009 - 2026)

Edwards Lifesciences' Depreciation & Amortization (CF) history runs 18 years deep, the most recent figure standing at $40.9 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 11.75% year-over-year to $40.9 million in Q1 2026; TTM through Mar 2026 was $160.9 million, a 4.96% increase from a year earlier, with the FY2025 full-year figure at $156.6 million, up 0.9% from the prior year.
• Depreciation & Amortization (CF) fell to $40.9 million in Q1 2026 per EW's latest filing, from $42.7 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $42.7 million in Q4 2025 and bottomed at $34.1 million in Q2 2022.
• The 5-year median for Depreciation & Amortization (CF) is $36.7 million (2023), against an average of $37.5 million.
• Biggest YoY gain for Depreciation & Amortization (CF) was 16.08% in 2024; the steepest drop was 6.5% in 2024.
• Year by year, Depreciation & Amortization (CF) stood at $35.4 million in 2022, then rose by 3.67% to $36.7 million in 2023, then climbed by 16.08% to $42.6 million in 2024, then grew by 0.23% to $42.7 million in 2025, then decreased by 4.22% to $40.9 million in 2026.
• Per Business Quant, the three latest EW Depreciation & Amortization (CF) figures stand at $40.9 million (Q1 2026), $42.7 million (Q4 2025), and $39.2 million (Q3 2025).